Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of BI 425809 in Healthy Male Volunteers
NCT02362516Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2015
- Primary completion
- Jun 2015
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of iclepertin in schizophrenia (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 14h, Area Under the Concentration-time Curve of BI 425809 in CSF Over the Time Interval From 0 to 14h and 4 more. Started Feb 2015; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02362516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362516.